Rozsa Schlenker‐Herceg

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Roland M. du Bois, Ganesh Raghu et al. · New England Journal of Medicine · 2014 · 4.6K citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Kevin R. Flaherty, Athol U. Wells, Vincent Cottin et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacotherapy +11

Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement

Robert P. Baughman, Marjolein Drent, Mani S. Kavuru et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 709 citations

Medicine, Immunology, Pharmacotherapy +12

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 559 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma

Sally E. Wenzel, Peter J. Barnes, Eugene R. Bleecker et al. · American Journal of Respiratory and Critical Care Medicine · 2009 · 457 citations

Medicine, Pharmacology, Pharmacotherapy +14